AnalystsMatthew KellerMatthew Keller's Stock Forecasts
AnalystsMatthew Keller
Sectors:
Industries:
Analyst Ranking
Bottom 28%
#3714 out of 5100 analysts
Average Return
-0.72%
Win Rate
63%5 out of 8
Risk vs Reward
Poor
Good
Matthew Keller's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Galectin Therapeutics IncGALT | +47.07% | $3.76 | $5.53 | 2025-08-13 - 2025-11-13 | Buy |
Fibrogen IncFGEN | +14.23% | $7.94 | $9.07 | 2025-08-06 - 2025-11-13 | Buy |
Acurx Pharmaceuticals IncACXP | +10.49% | $4.29 | $4.74 | 2025-09-29 - 2025-11-13 | Buy |
Acurx Pharmaceuticals IncACXP | +6.88% | $4.44 | $4.74 | 2025-08-11 - 2025-11-13 | Buy |
Gyre Therapeutics IncGYRE | +4.12% | $7.76 | $8.08 | 2025-08-25 - 2025-11-13 | Buy |
Matthew Keller Analyst Color
Get additional color on Matthew Keller's coverage of popular stocks
Matthew Keller's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Acurx Pharmaceuticals IncACXP | 2 | Buy | $31.00 | +554.01% | Reiterates | a month ago |
Fibrogen IncFGEN | 2 | Buy | $43.00 | +374.09% | Reiterates | 2 months ago |
Inflarx NvIFRX | 1 | Buy | $6.00 | +372.44% | Assumes | 2 months ago |
Gyre Therapeutics IncGYRE | 1 | Buy | $18.00 | +122.77% | Initiates Coverage On | 3 months ago |
Phio Pharmaceuticals CorpPHIO | 1 | Buy | $14.00 | +879.02% | Reiterates | 3 months ago |
Galectin Therapeutics IncGALT | 1 | Buy | $6.00 | +8.50% | Reiterates | 3 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.